Drug-eluting stents (DES) are placed inside blocked or narrowed coronary arteries, where they slowly release the drug to inhibit cell proliferation. Introduced in 2003, DES comprise a mesh-like tubular structure of thin wire; the drug and drug carrier which is a polymer or a mixture of polymer. Biostable or biodegradable polymers could be used to make the DES. Cytostatic drugs such as sirolimus or a cytotoxic drugs are used in these stents. DES have proven to be very successful in treating acute myocardial infarction, atherosclerosis, angina pectoris, and multiple vessel disease with reduced restenosis, allergic reactions, etc. compared to bare metal stents. These stents have almost eliminated the risk of restenosis, negative vessel remodeling, early stent thrombosis, and other side effects that occurred frequently due to the use of traditional bare metal stents (BMS). Post its discovery and approval to be utilized in coronary arteries, these stents have replaced BMS in the treatment of various cardiovascular disorders.
Read Report Overview @ https://www.transparencymarketresearch.com/drug-eluting-stents-market.html
The global drug-eluting stents market can be segmented based on the generation of DES, stent coating type, end-users, and region. In terms of generation of DES, the market can be categorized into first generation DES, second generation DES, and third generation DES. Based on stent coating, the market can be divided into biocompatible coatings, drug-delivery coatings, and polymer-free coatings/surfaces. In terms of end-users, the market can be classified into hospitals, ambulatory surgical centers, and cardiac centers.
According to the World Health Organization, coronary heart disease (CAD) accounted for nearly 7.2 million deaths in 2002. Moreover, the Centers for Disease Control and Prevention (CDC) stated that coronary heart disease accounted for around 370,000 deaths in the U.S. every year, and around 1 in every 13 individuals suffer from coronary artery disease in the country. In Europe, CAD accounts for nearly 1.9 million deaths each year. Moreover, 1 in every 5 individual (21% men, 22% women) succumb to coronary artery disease in the Europe. The disease is also one of the most common causes of premature deaths (aged <65 years) and accounts for nearly 401,000 deaths in Europe each year. Therefore, high prevalence of coronary artery diseases would increase the demand for percutaneous coronary interventions (PCIs), which could further propel the growth of the drug-eluting stents market. In addition, decrease of in-stent restenosis, increased efficiency, and a significant reduction in revascularization procedures with DES are the key factors that fuelled the growth of DES market in the past. The DES market growth would further be pulled by continuous launch of third generation DES that overcome limitations associated with BMS or second generation DES and wide usage of DES in emerging nations.
Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30632
Key players operating in the global drug-eluting market include Abbott Laboratories, Inc., Medtronic, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, B. Braun Melsungen AG, Cook Medical, Cardinal Health, Johnson & Johnson, and Terumo Corporation.